0024 GMT - Ebos's pharmacy business was the standout of its 1H result, undermining the investment case of stock bears, Forsyth Barr says. Negative views toward Ebos have centered on the loss of the Chemist Warehouse contract to Sigma Healthcare, and 60-day dispensary changes creating a challenging backdrop for Community Pharmacy growth and margins, analyst Matt Montgomerie says. However, Ebos looks set to beat its original A$300 million target for pharmacy customer wins. Sales at its Terry White business are also up 11%, indicating it has gained market share, Forsyth Barr says. "We remain confident Ebos will hit the top end of its Ebitda guidance range," says Forsyth Barr, upgrading the stock to outperform from neutral. Ebos's New Zealand-listed shares are down 0.8%. (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
February 19, 2025 19:24 ET (00:24 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。